Moderna's mRNA Melanoma Vaccine Delivers Historic Trial Results, Sending Shares Up 145%

Moderna Stock More Than Doubles After Melanoma Vaccine Breakthrough

Moderna (MRNA) shares exploded higher on Wednesday after the Cambridge-based biotech company and its partner Merck (MRK) unveiled clinical trial data showing their experimental mRNA-based melanoma vaccine successfully reduced the cancer's return in high-risk patients — a finding researchers are calling a landmark development in oncology.

What the Numbers Show

Moderna's stock climbed $91.52, or approximately 145%, reaching $154.48 during morning trading after briefly touching an intraday high of $163. Merck shares also moved meaningfully higher, gaining $14.35, or 10.6%, to trade at $149.52. The dramatic surge for Moderna marked one of the company's most significant single-session moves since its COVID-19 vaccine era.

The two companies tested a personalized cancer vaccine called intismeran alongside Merck's established cancer immunotherapy drug Keytruda. The combination was evaluated in patients who had already undergone surgery to remove a melanoma tumor. Trial results indicated the dual-drug approach both delayed the cancer's return and helped prevent it from spreading to other organs — two critical metrics in post-surgical cancer care.

The companies have not yet published the full data but plan to present their findings to regulatory authorities at an upcoming international medical conference.

Why This Trial Matters

Melanoma is among the most dangerous forms of skin cancer. According to the Skin Cancer Foundation, more than 234,680 melanoma cases are projected to be diagnosed in the United States in 2026, with over 8,500 expected deaths this year alone. The disease originates in melanocytes — the cells responsible for skin pigmentation — and becomes life-threatening when those cells grow uncontrollably and metastasize.

Existing treatments have historically struggled to keep the disease at bay after surgery, making the concept of adjuvant therapy — treatment given post-operatively to reduce recurrence risk — a critical area of research.

Professor Georgina Long, the trial's principal investigator and chair of Melanoma Medical Oncology and Translational Research at the University of Sydney, described the results as unprecedented. "Today's results represent a landmark moment for adjuvant melanoma treatment," she said in a statement Wednesday, noting that the study is the first of its kind to demonstrate that treatment can "reduce the risk of recurrence or death in patients" with this form of cancer.

Long added that the findings have "the potential to establish a new treatment paradigm in the adjuvant melanoma setting, helping patients remain cancer-free for longer."

What Executives Are Saying

Senior leaders at both companies framed the results as a turning point — not just for melanoma, but for cancer treatment more broadly.

Dr. Dean Y. Li, president of Merck Research Laboratories, emphasized the strategic logic of treating cancer earlier in its progression. "By intervening earlier in the course of disease, when many cancers are considered most treatable, the goal of adjuvant therapy given after surgery is to increase the possibility of cure for more patients," he said.

Moderna CEO Stéphane Bancel called the moment a "pivotal" one for cancer research overall. "For many years, the idea of creating an mRNA treatment designed specifically for an individual patient's cancer was aspirational," Bancel said. "We are now helping turn that vision into a reality."

The personalized nature of intismeran is particularly noteworthy — it represents a broader ambition within the mRNA therapeutics space to move beyond infectious disease and into oncology, leveraging the same platform technology that powered COVID-19 vaccines.

Context: Where Moderna Stands Today

Despite Wednesday's massive rally, Moderna shares remain well below the company's pandemic-era highs from late 2021 and early 2022, when global demand for its COVID-19 vaccine drove the stock to extraordinary valuations. The company has spent the intervening years navigating declining vaccine revenues and investor skepticism about its pipeline.

This melanoma data could represent a meaningful inflection point for the company's long-term narrative — shifting the conversation from COVID dependence toward a diversified mRNA platform with oncology applications.

What to Watch Next

Key milestones ahead include the formal presentation of trial data at the upcoming international medical meeting, followed by potential regulatory submissions. Analysts and investors will be closely watching how the FDA and other global health regulators respond to the data, what the eventual label and patient population might look like, and how Moderna and Merck plan to price and commercialize the therapy if approved. The timeline from data presentation to potential regulatory approval will be a critical factor in how the market continues to price both companies' shares.